FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees
This article was originally published in The Pink Sheet Daily
The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.
You may also be interested in...
FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections
A Federal Register notice outlines the new user fee amounts and suggests that President Obama’s budget projections anticipated as many as 10 marketing applications, but the mix of INDs and full applications is unknown.
Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach
The forecast for 2012 approvals looks sunny. FDA approved almost as many novel drugs in the first half of 2012 as it did in the first half of its record-breaking 2011 – and the agency has more than twice as many pending NME applications with user fee goals in the next six months as it had last year.
NDA, BLA Submissions Expected To Fall Again in FY 2011
FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.